Getting Chimeric Antigen Receptor (CAR)-T Cell Therapy to Sydney
In hematological malignancies, engineered T cell receptors (TCR) and chimeric antigen receptors (CAR) are new powerful T-cell based immune therapies that target specific antigens.
Future opportunities for CAR therapy are impressive. Our haematology department is developing the necessary recources required so that many physicians can provide rapid introduction of CAR-T cell therapy.
